A composition for repairing oocytes in female ovaries and its preparation method and application
Patent Information
- Application Number
- CN202410251201.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-05
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-03-05
AI Technical Summary
The existing technology has limited effect in protecting ovarian functions and cannot effectively repair premature ovarian failure and ovarian damage, affecting women's physiological and mental health.
A composition containing stem cells and polypeptides that upregulate P-AMPK expression is developed to repair ovarian function by isolating endometrial stem cells from menstrual blood at the beginning of menstrual period and isolating polypeptides with anti-aging effects from Polygonum multiflorum.
It significantly improves follicle secretion and E2 secretion, improves ovarian function, has good anti-ovarian aging and repair effects, and can effectively reduce premature ovarian failure and infertility caused by chemotherapy drugs.
Smart Images

Figure CN118121680B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a composition for repairing egg cells in female ovaries, and a preparation method and application thereof. Background Art
[0002] The ovary is an important gonadal organ of women. Women's growth, development, and reproduction are closely related to ovarian function and the quality of oocytes. Ovarian function and fertility are important factors affecting women's quality of life. Currently, women are troubled by many problems such as premature ovarian failure and ovarian loss, which seriously affect their physical and mental health.
[0003] Therefore, it is particularly important to explore drugs that protect the ovaries. At present, there are many methods for treating premature ovarian failure and ovarian loss, such as using exosomes or biological peptides. For example, the prior art CN 111593017 B discloses the use of human amniotic epithelial cell exosomes in the preparation of drugs for repairing ovarian function. Animal experiments have confirmed that human amniotic epithelial cell exosomes can significantly increase the number of ovarian follicles damaged by chemotherapy, inhibit acute ovarian vascular damage and granulosa cell apoptosis induced by chemotherapy drugs, and partially inhibit the activation of primordial follicles induced by chemotherapy drugs. Therefore, it can be used to repair ovarian function after chemotherapy damage, reduce the damage of chemotherapy drugs to the ovaries, prevent and treat premature ovarian failure caused by chemotherapy drugs, or prevent and treat infertility caused by chemotherapy. The present invention also provides a method for preparing human amniotic epithelial cell exosomes, which shows a very significant repair effect on chemotherapy-damaged ovaries.
[0004] Prior art CN 109929799 B discloses human umbilical cord mesenchymal stem cell exosomes and their preparation method and application. The preparation method comprises the following steps: collecting human umbilical cord tissue and extracting umbilical cord mesenchymal stem cells; the obtained umbilical cord mesenchymal stem cells are centrifuged to extract exosomes. The HucMSC exosomes of the present invention can activate primordial follicles and promote the development of follicles in newborn mice. The quality of mature oocytes obtained after the follicles mature is not affected. HucMSC exosomes can improve the reproductive function of elderly mice. After the exosomes are injected into the ovarian cysts of elderly mice and mated with male mice, the number of litters born in the experimental group was significantly higher than that in the control group.
[0005] Prior art CN 113502315 B discloses a tilapia skin peptide and a preparation method thereof and an application thereof in improving premature ovarian failure, belonging to the field of polypeptide extraction technology, and comprising the following steps: (1) defatting and drying the pretreated tilapia skin; (2) enzymolyzing the dried tilapia skin with a protease; (3) inactivating the enzymolysis solution, centrifuging, ultrafiltering, concentrating, and freeze-drying to obtain the tilapia skin peptide; the tilapia skin peptide prepared by the present invention has a molecular weight of mostly small molecular weight polypeptides below 6KDa.
[0006] Prior art CN 113786474 B and CN 113633754 B disclose that ovarian stem cells were obtained by separation and preparation, and active peptides with anti-aging effects were isolated from Polygonum multiflorum. When the stem cells and active peptides were used together to treat an ovarian aging model, it was found that the secretion of follicles and E2 could be effectively promoted, and the secretion had a good anti-ovarian aging effect.
[0007] Prior art CN 112933215 B discloses an application of SIRT1 in the preparation of ovarian function protection drugs, specifically, an adenovirus vector is injected in situ through the ovary to achieve gene upregulation in the ovary, and the purpose of ovarian function reconstruction is achieved by repairing the damaged part.
[0008] CN 114767667 B discloses that the effective ingredients in Manlong liquid can resist oxidative damage by activating P-AMPK protein. The effective ingredients in Manlong liquid are psoralen derivatives. The anti-oxidative damage effect is anti-ovarian oxidative damage effect. Psoralen derivatives can improve the damaging effect of cyclophosphamide on mouse ovaries.
[0009] However, the above-mentioned prior art has limited effect in protecting the ovaries. In order to protect women's health and enrich the development of prior art, the present invention will develop a new ovarian protection composition for repairing egg cells in female ovaries. Summary of the invention
[0010] The present invention first provides a composition for repairing oocytes in female ovaries in order to achieve the above-mentioned purpose, wherein the composition comprises stem cells and / or polypeptides that upregulate the expression of P-AMPK.
[0011] In some examples, the composition consists of stem cells and a polypeptide that upregulates the expression of P-AMPK.
[0012] In some examples, the stem cells are endometrial stem cells.
[0013] In some examples, the raw material used in the method for preparing endometrial stem cells is menstrual blood at the beginning of the menstrual period.
[0014] In some examples, the amino acid sequence of the polypeptide is shown in SEQ ID NO.1.
[0015] In some examples, the polypeptide is isolated from Polygonum multiflorum.
[0016] In order to achieve the above object, according to a second aspect of the present invention, a method for preparing the above composition is provided, the preparation method comprising the following steps:
[0017] (1) Isolating endometrial stem cells from early menstrual blood;
[0018] (2) A polypeptide is isolated from Polygonum multiflorum, the amino acid sequence of which is shown in SEQ ID NO.1
[0019] (3) The components of step (1) and step (2) are mixed in proportion to obtain a composition.
[0020] In some examples, the step (1) further comprises the steps of digestion and culturing.
[0021] In some examples, the step (1) further comprises the step of antigen identification.
[0022] In order to achieve the above object, according to the third aspect of the present invention, there is provided an application of the above composition, wherein the application is for preparing a drug for treating premature ovarian failure or repairing ovarian oocytes.
[0023] The beneficial effects of the above technical solution of the present invention are as follows:
[0024] The present invention obtains endometrial stem cells by separation and preparation, and simultaneously separates active peptides with anti-aging effects from Polygonum multiflorum. When the stem cells and the active peptides are used together for the treatment of an ovarian aging model, it is found that the secretion of follicles and the secretion of E2 can be effectively promoted, and the secretion has good effects on anti-ovarian aging and ovarian repair. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 is the expression level of P-AMPK in different experimental groups. DETAILED DESCRIPTION
[0026] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0027] Example 1 Isolation and preparation of stem cells
[0028] 1) Obtaining endometrial stem cells: Collecting menstrual blood at the beginning of menstruation and processing it to obtain endometrial cell tissue;
[0029] 2) Digestion: Cut the endometrium obtained in step 1) into 2 mm 3 The fragments were digested by adding pancreatin I and collagenase IV (1:1) at 37°C for 2 h. After digestion, they were rinsed in physiological saline and centrifuged. The obtained precipitate was washed with physiological saline and blown evenly, then passed through a 40 μm cell sieve, the filtrate was collected, and the supernatant was discarded by centrifugation to obtain the cell precipitate.
[0030] 3) Primary culture: Add DMEM / F12 culture medium containing 10 ng / ml EGF to the cell pellet obtained in step 2) to obtain a single cell suspension. 4 The cells were inoculated into a culture dish at a concentration of 100 / mL and cultured for 5 h. The non-adherent cells in the culture dish were transferred to a new culture dish. The culture medium was replaced and cultured for another 5 days. The adherent cells were collected and marked as P0 cells. P0 endometrial stem cells were taken for surface antigen detection. The marker antigen detection results are shown in Table 1.
[0031] Table 1 Antigen identification results
[0032] CD73 CD90 CD34 98.1%* 96.1%* 0.013%
[0033] 4) When the cell fusion rate reaches about 85-90%, the P0 cells are subcultured to obtain P3 cells for use.
[0034] Example 2 Preparation of polypeptide
[0035] Take 5g of Polygonum multiflorum, add 5 times the amount of distilled water to soak for 2h, boil for 30min over low heat, and filter. Add 3 times the amount of water to the residue and continue to decoct for 20min, ultrasonicate for 10min under 50w power ultrasonic crushing conditions, and filter. Mix the two filtrates, centrifuge at 8000r / min for 10min, and take the supernatant. Add 0.5% composite protease for enzymatic hydrolysis at 37℃ for 1h and then terminate the enzymatic hydrolysis. Sequentially apply CM-Sepharose Fast Flow and Sephadex G-50 chromatography, and then reverse-phase high-performance liquid chromatography to obtain different polypeptide components. According to the characteristics of polypeptide upregulating SIRT1 expression, 3 polypeptides with the characteristics of upregulating P-AMPK protein expression were screened and obtained. MALDI-ToFMS was used to determine the two polypeptides with better effects, and their amino acid sequences were P1: QFLFQGKFLPYWSSMWVQ (SEQ ID NO.1).
[0036] Example 3 Experiment on mouse premature ovarian failure model
[0037] ICR mice with normal estrous cycle were randomly divided into model group, stem cell transplantation group, peptide treatment group, stem cell + peptide combination group and blank control group, with 30 mice in each group. The model group, stem cell transplantation group, peptide treatment group and stem cell + peptide combination group were injected with 0.1 mL of cyclophosphamide solution (120 mg / kg) and busulfan solution (12 mg / kg) intraperitoneally once. Vaginal secretion smears were gently taken with cotton swabs every day, and Papanicolaou staining was performed to observe the changes in vaginal exfoliated cells. When continuous estrus was observed for 10 consecutive days, it was considered that premature ovarian failure was successfully modeled. On the 14th day of modeling, the stem cell transplantation group was injected with 0.1 mL of the endometrial stem cell suspension (1x10 8The peptide group was injected with 0.1 mL of P1 peptide (10 mg / kg) via the tail vein on the 14th day of modeling, and the injection was repeated every 4 days for a total of 5 times. The stem cell + peptide combination group was injected with 0.1 mL of endometrial stem cell suspension (1x10 8 / mL) and P1 polypeptide (10mg / kg) 0.1mL, repeated once every 4 days, a total of 5 times. The modeling group and the blank control group were injected with an equal amount of normal saline via the tail vein each time.
[0038] Reproductive hormone determination: The serum of each group of mice was obtained by tail snip method, and the levels of follicle stimulating hormone (FSH) and estradiol (E2) of mice were detected by chemiluminescence method. All serums were detected by the same batch of reagents. The results are shown in Table 2.
[0039] Table 2 Comparison of FSH and E2 in each group of mice
[0040] Group FSH / (mlU / mL) E2 / (pg / mL) Model Group 4.98±0.28 34.17±2.78 Blank control group 2.81±0.19 46.28±3.15 Stem cell transplantation group 3.21±0.28 38.88±2.75 Peptide treatment group 3.41±0.28 39.18±3.02 Stem cell + peptide combination group 2.85±0.22 45.25±2.88
[0041] From the results in Table 2, it can be seen that compared with the control, the E2 secretion of the mouse model group decreased and the FSH secretion increased, indicating that the mice had ovarian failure. After treatment with the combined group, the E2 secretion of the mice increased and the FSH secretion decreased, which was close to the hormone secretion level of normal rats, indicating that the combined group can effectively improve the ovarian function.
[0042] The mice from each group were killed by cervical dislocation, and the bilateral ovarian tissues were obtained and frozen sections were observed under a fluorescence microscope (x400) for histological changes of the ovaries. The results are shown in Table 3.
[0043] Table 3 Comparison of follicle numbers in each group
[0044] Group Total follicle count Model Group 13.5±3.13 Blank control group 42.3±3.91 Stem cell transplantation group 32.3±2.14 Peptide treatment group 32.8±2.75 Stem cell + peptide combination group 41.1±2.91
[0045] From the results in Table 3, it can be seen that the total number of follicles in the model group was significantly less than that in the blank control group. However, after the combined treatment, the total number of follicles in the model group was significantly increased, which was basically close to the number of follicles in normal mice, indicating that it has a good effect in restoring ovarian function.
[0046] Example 4 Western blot detection
[0047] Western blot was used to detect the expression of P-AMPK protein in the model group, peptide treatment group, stem cells, and stem cell + peptide combination group. The cells were taken after 48 hours of the above grouping, and the cells were collected by centrifugation after trypsin digestion. After RIPA lysis solution, the supernatant was collected by centrifugation at 12000r / min at 4℃. After BCA protein quantification, the protein was boiled with protein loading buffer and stored at -20℃ for later use. A 12% polyacrylamide gel was prepared, and the sample amount was 20μg for SDS-PAGE electrophoresis. After the electrophoresis, wet transfer (PVDF) was performed and blocked with skim milk powder for 2 hours. The primary antibody was P-AMPK (1:500) or anti-GAPDH (1:5000), and the secondary antibody was horseradish peroxide-labeled goat anti-rabbit antibody (I:10000). After adding ECL luminescent liquid, the imaging system was used for analysis. The results are shown in Figure 1 shown.
[0048] Depend on Figure 1 It can be seen that compared with the control group, the P-AMPK level in the injury model group was significantly decreased, and the P-AMPK level could be significantly increased after treatment with the peptide treatment group, stem cells, and stem cell + peptide combination group (P < 0.01).
[0049] It should be understood that the above are only some embodiments of the present invention. It should be pointed out that for ordinary technicians in this field, other modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. A composition for repairing oocytes in female ovaries, characterized in that: The composition consists of stem cells and polypeptides that upregulate the expression of P-AMPK; The stem cells are endometrial stem cells; The amino acid sequence of the polypeptide is shown in SEQ ID NO.
1.
2. The composition according to claim 1, characterized in that The raw material used in the method for preparing endometrial stem cells is menstrual blood at the beginning of menstruation.
3. A method for preparing the composition according to any one of claims 1 to 2, the method comprising the following steps: (1) Isolating endometrial stem cells from early menstrual blood; (2) A polypeptide is isolated from Polygonum multiflorum, wherein the amino acid sequence of the polypeptide is shown in SEQ ID NO.1; (3) The components of step (1) and step (2) are mixed in proportion to obtain a composition.
4. The method according to claim 3, characterized in that The step (1) further comprises the steps of digestion and culturing.
5. The method according to claim 3, characterized in that: The step (1) also includes the step of antigen identification.
6. The use of the composition according to any one of claims 1 to 2, characterized in that: The application is to prepare medicine for treating premature ovarian failure or repairing ovarian oocytes.
